| Product Code: ETC6192056 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australia strongyloidiasis treatment market is influenced by the presence of this parasitic infection, especially in Indigenous and tropical northern populations. The demand for effective anthelmintic therapies like ivermectin is supported by public health screening programs and growing awareness. Challenges remain in terms of diagnosis and treatment adherence, but government-led interventions aim to reduce disease burden.
The strongyloidiasis treatment market in Australia is expanding due to increased screening in high-risk populations, especially Indigenous communities. Ivermectin remains the primary treatment, but research into alternative therapies is being encouraged by government and academic partnerships.
Strongyloidiasis treatment in Australia is hampered by underdiagnosis, especially in Indigenous and remote communities, due to low awareness among healthcare providers. Access to antiparasitic drugs like ivermectin is limited in remote areas, and surveillance systems are not well-established to monitor prevalence and treatment efficacy.
Investment opportunities in the Strongyloidiasis Treatment Market are emerging as public health campaigns and awareness increase about parasitic infections in remote and tropical regions of Australia. Pharmaceutical companies producing anti-parasitic drugs, particularly ivermectin-based treatments, are well-positioned to expand market share. There`s also potential for partnerships with government health programs targeting Aboriginal communities and rural health initiatives, making this a niche but impactful investment opportunity.
Strongyloidiasis, more prevalent in Indigenous and remote communities, has received policy attention through targeted health initiatives. The Australia government, under the National Aboriginal and Torres Strait Islander Health Plan, supports screening and treatment programs for parasitic infections. Funding through public health campaigns aims to improve sanitation and access to anthelmintic medications like ivermectin, especially in endemic areas.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Strongyloidiasis Treatment Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Strongyloidiasis Treatment Market - Industry Life Cycle |
3.4 Australia Strongyloidiasis Treatment Market - Porter's Five Forces |
3.5 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By Diagnosis Tests, 2021 & 2031F |
3.7 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.8 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By Dugs Class, 2021 & 2031F |
3.9 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By End Users, 2021 & 2031F |
3.10 Australia Strongyloidiasis Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Strongyloidiasis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing awareness about strongyloidiasis in Australia |
4.2.2 Increasing prevalence of strongyloidiasis infections |
4.2.3 Technological advancements in diagnostic tools and treatment options |
4.3 Market Restraints |
4.3.1 Limited availability of effective treatment options |
4.3.2 High cost of treatment and diagnostic procedures |
4.3.3 Lack of skilled healthcare professionals specializing in strongyloidiasis treatment |
5 Australia Strongyloidiasis Treatment Market Trends |
6 Australia Strongyloidiasis Treatment Market, By Types |
6.1 Australia Strongyloidiasis Treatment Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Acute Strongyloidiasis, 2021- 2031F |
6.1.4 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Chronic Strongyloidiasis, 2021- 2031F |
6.2 Australia Strongyloidiasis Treatment Market, By Diagnosis Tests |
6.2.1 Overview and Analysis |
6.2.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Duodenal Aspiration Test, 2021- 2031F |
6.2.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Sputum Culture Test, 2021- 2031F |
6.2.4 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Stool Test, 2021- 2031F |
6.2.5 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Complete Blood Count (CBC) Test, 2021- 2031F |
6.2.6 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Blood Antigen Test, 2021- 2031F |
6.3 Australia Strongyloidiasis Treatment Market, By Treatment Type |
6.3.1 Overview and Analysis |
6.3.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By First Line Therapy, 2021- 2031F |
6.3.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Second Line Therapy, 2021- 2031F |
6.4 Australia Strongyloidiasis Treatment Market, By Dugs Class |
6.4.1 Overview and Analysis |
6.4.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Antiparasitic Drugs, 2021- 2031F |
6.4.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Strongyloidiasis Treatment Market, By End Users |
6.5.1 Overview and Analysis |
6.5.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Clinics, 2021- 2031F |
6.5.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.4 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Australia Strongyloidiasis Treatment Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Direct Tender, 2021- 2031F |
6.6.3 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.4 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.5 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.6 Australia Strongyloidiasis Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Strongyloidiasis Treatment Market Import-Export Trade Statistics |
7.1 Australia Strongyloidiasis Treatment Market Export to Major Countries |
7.2 Australia Strongyloidiasis Treatment Market Imports from Major Countries |
8 Australia Strongyloidiasis Treatment Market Key Performance Indicators |
8.1 Number of diagnosed strongyloidiasis cases in Australia |
8.2 Adoption rate of new treatment technologies |
8.3 Research and development investments in strongyloidiasis treatment |
8.4 Patient satisfaction and treatment outcomes |
8.5 Number of healthcare facilities offering specialized strongyloidiasis treatment |
9 Australia Strongyloidiasis Treatment Market - Opportunity Assessment |
9.1 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By Diagnosis Tests, 2021 & 2031F |
9.3 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.4 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By Dugs Class, 2021 & 2031F |
9.5 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By End Users, 2021 & 2031F |
9.6 Australia Strongyloidiasis Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Strongyloidiasis Treatment Market - Competitive Landscape |
10.1 Australia Strongyloidiasis Treatment Market Revenue Share, By Companies, 2024 |
10.2 Australia Strongyloidiasis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here